VA healthcare GLP-1 access — veteran members share experiences

Dr.AddMedPHL said:

My insurance denied my PA related to cost and coverage.

Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives:

1. Prior authorization appeal with peer-to-peer review
2. Manufacturer copay card (for commercial insurance)
3. Patient assistance programs (Novo Nordisk, Eli Lilly)
4. Compounded medication from a 503B pharmacy ($137/month)
5. Canadian pharmacy (requires prescription, ~40-60% savings)

Don't let cost prevent access to effective treatment. There are options at every price point.

sarah.morrison said:

Dr.SurgeonPGH said: ...my insurance denied cost and coverage coverage because...

Saving this. It is the first explanation that did not require me to already understand it. I will report back once I have actually tried it.

Dr.AddMedPHL said:

My insurance denied my PA related to cost and coverage.

Dr.AddMedPHL said:

...compounded vs brand cost and coverage...

This debate comes up weekly and I think both sides have valid points:

Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable

Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility

My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.

SteveThurs said:

Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

Telehealth prescriber review for cost and coverage: I've used 3 different telehealth platforms to get my GLP-1 prescription. Comparison:

I settled on the one that required labs — it shows they care about safety, not just prescribing volume.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Carry on.